文献速递疝与腹壁外科围术期管理与 ERAS

开放复杂腹壁重建中合成补片与生物补片的远期结局比较:至少5年随访

Open, complex abdominal wall reconstruction with synthetic versus biologic mesh: Outcomes with a minimum of 5-year follow-up.
PubMed 文献 · Surgery · 2025-12-11

本研究通过倾向性评分匹配比较开放复杂腹壁重建中合成补片与生物补片的结局,随访超过5年。生物补片组手术时间、费用及延迟一期闭合率更高,但两组在疝复发、伤口裂开、感染、血清肿及补片感染方面无差异。生物补片在污染环境中使用更频繁,但效果与合成补片相当。

要点

  • 复杂腹壁重建中,生物补片与合成补片的疝复发和伤口并发症无显著差异。
  • 生物补片组手术时间、手术室费用及总费用显著高于合成补片组。
  • 生物补片更多用于污染伤口,延迟一期闭合率更高,但感染相关结局无差异。

核心结论

  • 在倾向性匹配的复杂大型腹壁重建患者中,生物补片与合成补片在至少5年随访时疝复发和伤口并发症结局相当。
  • 尽管生物补片更常用于污染环境,但其有效性不劣于合成补片。

研究设计与样本

  • 回顾性队列研究,查询前瞻性维护数据库,纳入开放腹壁重建且随访超过5年的患者。
  • 采用1:1倾向性评分匹配,匹配因素包括年龄、体重指数、吸烟状态、糖尿病、美国麻醉医师协会分级和缺损情况,共生成76对匹配患者。

主要发现

  • 伤口分级(疾病控制与预防中心2-4级)在两组间差异显著(15.8% vs 81.6%;P < .001)。
  • 缺损面积(244.6±267.0 cm2 vs 254.1±141.4 cm2;P = .0866)和补片放置位置(腹膜前97.6% vs 100.0%;P = .497)相似,但补片面积不同(943.8±415.0 cm2 vs 581.5±297.4 cm2;P < .001)。
  • 生物补片组手术时间更长(189.9±73.2分钟 vs 229.3±95.7分钟;P = .010),手术室费用更高($12,682±$7,352 vs $22,293±$14,373;P < .001),总费用更高($58,265±$27,712 vs $119,740±$69,670;P < .001)。
  • 生物补片组因伤口污染更常采用延迟一期闭合(1.3% vs 30.3%;P < .001)。
  • 术后伤口裂开(11.8% vs 11.8%)、感染(0.5% vs 14.5%)、血清肿(17.1% vs 14.5%)、补片感染(3.9% vs 2.6%)和疝复发(11.8% vs 9.2%)均无显著差异(所有P > .05)。

临床怎么用

  • 在复杂腹壁重建中,生物补片和合成补片均可选择,疝复发和伤口并发症风险相似。
  • 生物补片适用于污染或感染风险高的伤口,但需考虑其更高的手术时间和费用。

局限性

  • 回顾性设计,尽管采用倾向性评分匹配,仍可能存在未测量的混杂因素。
  • 伤口分级在两组间差异显著,生物补片组污染伤口比例更高,可能影响结果解释。
  • 补片面积在两组间存在显著差异,可能对结局产生一定影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Reported outcomes for synthetic mesh versus biologic mesh in open abdominal wall reconstruction vary widely and are influenced by mesh type, location, fascial closure, wound complications, and patient characteristics. Little comparative data controlling for these variables or long-term results exists. This study compared outcomes between synthetic mesh and biologic mesh with >5 years of follow-up. METHODS: A prospectively maintained database was queried for open abdominal wall reconstruction with >5 years of follow-up. A 1:1 propensity score match was performed based on age, body mass index, tobacco status, diabetes, American Society of Anesthesiologists classification, and defect. Standard descriptive and comparative statistics were calculated. RESULTS: The 76 pairs generated were well balanced for age, body mass index, comorbidities, American Society of Anesthesiologists score, and rate of recurrent hernia. Wound class varied significantly (Centers for Disease Control and Prevention class 2-4: 15.8% vs 81.6%; P < .001). Defect size (244.6± 267.0 cm2 vs 254.1 ± 141.4 cm2; P = .0866) and mesh placement (preperitoneal 97.6% vs 100.0%; P = .497) were similar; mesh size differed (943.8 ± 415.0 cm2 vs 581.5 ± 297.4 cm2; P < .001). There were no differences in component separation or fascial closure. Biologic mesh had increased operative time (189.9 ± 73.2 minutes vs 229.3.5 ± 95.7 minutes; P = .010), operating room charges ($12,682 ± $7,352 vs $22,293 ± $14,373; P < .001), and total charges ($58,265 ± $27,712 vs $119,740 ± $69,670; P < .001). Delayed primary closure was more frequent with biologic mesh secondary to wound contamination (1.3% vs 30.3%; P < .001). Postoperatively, there were no differences in wound dehiscence (11.8% vs 11.8%), infection (0.5% vs 14.5%), seroma (17.1% vs 14.5%), mesh infection (3.9% vs 2.6%), or hernia recurrence (11.8% vs 9.2%) (all P > .05). Follow-up averaged >7 years (3.2 ± 25.2 months vs 86.1 ± 24.5 months). CONCLUSION: In propensity-matched patients with complex, large abdominal wall reconstructions with at least 5 years of follow-up, biologic mesh and synthetic mesh yielded equivalent hernia recurrence and wound complication outcomes. Biologic mesh is as effective as synthetic mesh in abdominal wall reconstruction despite being more frequently used in a contaminated setting.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Wiley AJ, Jensen SM, Holland AM, et al. Open, complex abdominal wall reconstruction with synthetic versus biologic mesh: Outcomes with a minimum of 5-year follow-up. Surgery. 2025. PMID: 41387067. doi:10.1016/j.surg.2025.109961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。